Self-Study 2026: Updates on Treatments for Adult Acute Lymphoblastic Leukemia

Type: Individual•Format: On-demand

Acute lymphoblastic leukemia (ALL) is diagnosed in approximately 6,500 new patients annually in the United States. Treatment for ALL in adults has historically required intensive multi-agent chemotherapy regimens that incur significant toxicity, and outcomes have fallen short of the results achieved in the pediatric population. Strategies such as incorporating immunotherapy and TKIs have increased the efficacy of first-line treatment, and additional therapies such as chimeric antigen receptor (CAR) T-cells can produce durable responses in relapse.

This session will review recent literature describing newly developed regimens and therapeutic agents for the treatment of ALL with a focus on adult B-cell ALL. The articles discussed represent practice-changing advances to improve the safety and efficacy of treatments for both initial therapy and management of relapsed or refractory disease.

Updates on Treatments for Adult Acute Lymphoblastic Leukemia

Author: Leah B. Galloway, PharmD, BCOP - Clinical Pharmacist Specialist, Hematology/Transplant and Cellular Therapy

Learning Objectives

  1. Evaluate the safety and efficacy of a tyrosine kinase inhibitor and blinatumomab combination in first-line treatment of Ph+ ALL
  2. Describe the role of inotuzumab and blinatumomab in older adults with newly diagnosed ALL
  3. Develop a treatment plan for newly diagnosed B-cell ALL based on recent evidence for incorporating immunotherapy
  4. Discuss the safety and efficacy of a new chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel, in relapsed or refractory B-cell ALL

Get it here

Application Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.